OKYO Pharma Ltd(OKYO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
OKYO Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for OKYO Pharma Ltd (OKYO), a Healthcare sector company. OKYO is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of OKYO by reported 13-F value include Woodline Partners, Stonepine Capital Management, Maven Securities LTD, based on the most recent SEC filings. OKYO trades on the Nasdaq exchange and files with the SEC under CIK 1849296. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OKYO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for OKYO Pharma Ltd directly from SEC EDGAR.
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProTotal Assets
+138.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Total Assets | $3.7M +138.6% | $1.5M -70.4% | $5.2M +21.0% | $4.3M -39.4% | $7.1M | — |
Get alerted when OKYO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for OKYO Pharma Ltd including:
Top Institutional Holders of OKYO
Woodline Partners LP
$5.5M3,652,768 shStonepine Capital Management, LLC
$1.3M862,996 shMaven Securities LTD
$1.2M809,317 shBALYASNY ASSET MANAGEMENT L.P.
$870.9K580,596 shOpaleye Management Inc.
$562.8K375,204 shUBS Group AG
$82.5K55,009 shXTX Topco Ltd
$56.7K37,769 shCHOREO, LLC
$49.9K33,255 shQuantinno Capital Management LP
$49.9K33,255 shCerity Partners LLC
$19.2K12,812 sh
| Fund | Value | Shares |
|---|---|---|
| Woodline Partners LP | $5.5M | 3,652,768 |
| Stonepine Capital Management, LLC | $1.3M | 862,996 |
| Maven Securities LTD | $1.2M | 809,317 |
| BALYASNY ASSET MANAGEMENT L.P. | $870.9K | 580,596 |
| Opaleye Management Inc. | $562.8K | 375,204 |
| UBS Group AG | $82.5K | 55,009 |
| XTX Topco Ltd | $56.7K | 37,769 |
| CHOREO, LLC | $49.9K | 33,255 |
| Quantinno Capital Management LP | $49.9K | 33,255 |
| Cerity Partners LLC | $19.2K | 12,812 |
More Healthcare Companies
View all Healthcare →Put OKYO on your watchlist
Track score changes the day OKYO Pharma Ltd files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is OKYO a good stock to buy?
13F Pro's AI-powered analysis of OKYO Pharma Ltd (OKYO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OKYO are available on the OKYO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. OKYO is classified as a small company.
Which hedge funds own OKYO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OKYO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of OKYO Pharma Ltd's investment landscape.